Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nimesulide vs CBD Oil in TMD Pain
NCT04609748Phase 2
Key facts
- Status
- Unknown
- Start
- Jan 2021
- Primary completion
- Jul 2021
- Countries
- 1
- Sponsor
- Pomeranian Medical University in Szczecin
- Modality
- Small Molecules
- Drugs
- cannabidiol
- Conditions
- temporomandibular joint disorders (TMD)
01
Overview
Phase 2, randomised trial of cannabidiol in temporomandibular joint disorders (TMD) (2 arms), sponsored by Pomeranian Medical University in Szczecin. Primary endpoints: Pain relief at 15 days and Psychological conditions at 15 days. Status: unknown.
02
Design
2 arms- Study design
- Randomized
Nimesulide Arm
Nimesulide 100mg twice daily
CBD Oil Arm
Cannabidiol Oil 33.6mg twice daily
03
Who it enrols
Adult patients with pain from temporomandibular joint dysfunction, excluding those with acute ear/sinus inflammation, severe organ failure, pregnancy, or taking specific interacting medications.
04
Endpoints
Primary
Pain relief
Psychological conditions
Beyond the preview
Go deeper on NCT04609748.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04609748.